Pharmaceuticals company Cipla announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations stood at Rs 7,403.93 crore in Q2FY27, registering a QoQ increase of 4.00% compared to Rs 7,119.28 crore in Q1FY27, a YoY decrease of 2.44% compared to Rs 7,589.44 crore in Q2FY26, and stood at Rs 14,523.21 crore for H1FY27, down by 0.16% YoY from Rs 14,546.91 crore in H1FY26. Total income reached Rs 7,555.09 crore in Q2FY27, representing a QoQ expansion of 3.07% against Rs 7,330.18 crore in Q1FY27, a YoY drop of 3.86% against Rs 7,858.39 crore in Q2FY26, and aggregated Rs 14,885.27 crore for H1FY27, reflecting a YoY decline of 1.25% from Rs 15,074.42 crore in H1FY26. Profit before tax (PBT) was recorded at Rs 1,177.34 crore in Q2FY27, growing by 8.82% QoQ from Rs 1,081.93 crore in Q1FY27, reducing by 36.48% YoY from Rs 1,853.53 crore in Q2FY26, and totaled Rs 2,259.27 crore for H1FY27, a YoY contraction of 37.65% compared to Rs 3,623.46 crore in H1FY26. Net profit after tax (PAT) arrived at Rs 851.51 crore in Q2FY27, indicating an 8.40% QoQ growth from Rs 785.55 crore in Q1FY27, a 37.08% YoY contraction from Rs 1,353.37 crore in Q2FY26, and posted Rs 1,637.06 crore for H1FY27, shifting downwards by 38.11% YoY from Rs 2,644.98 crore in H1FY26. Earnings per equity share (EPS - Basic) stood at Rs 10.86 in Q2FY27, expanding by 11.16% QoQ from Rs 9.77 in Q1FY27, contracting by 35.09% YoY from Rs 16.73 in Q2FY26, and was recorded at Rs 20.63 for H1FY27, down by 37.08% YoY against Rs 32.79 in H1FY26. Standalone Financial Highlights: Revenue from operations was Rs 5,067.42 crore in Q2FY27, sliding by 0.20% QoQ compared to Rs 5,077.68 crore in Q1FY27, dropping by 3.03% YoY compared to Rs 5,225.72 crore in Q2FY26, and stood at Rs 10,145.10 crore for H1FY27, registering a YoY drop of 1.23% from Rs 10,271.89 crore in H1FY26. Total income reached Rs 5,214.98 crore in Q2FY27, marking a QoQ contraction of 1.98% against Rs 5,320.43 crore in Q1FY27, a YoY decrease of 4.84% against Rs 5,480.38 crore in Q2FY26, and aggregated Rs 10,535.41 crore for H1FY27, illustrating a YoY decline of 2.43% from Rs 10,797.62 crore in H1FY26. Profit before tax (PBT) recorded Rs 1,062.43 crore in Q2FY27, down by 7.90% QoQ from Rs 1,153.62 crore in Q1FY27, lower by 34.95% YoY from Rs 1,633.34 crore in Q2FY26, and reached Rs 2,216.05 crore for H1FY27, a YoY drop of 34.38% compared to Rs 3,377.29 crore in H1FY26. Net profit after tax (PAT) recorded Rs 787.03 crore in Q2FY27, dropping by 8.71% QoQ from Rs 862.16 crore in Q1FY27, declining by 34.98% YoY from Rs 1,210.53 crore in Q2FY26, and stood at Rs 1,649.19 crore for H1FY27, exhibiting a YoY decrease of 34.39% from Rs 2,513.66 crore in H1FY26. Earnings per equity share (EPS - Basic) was Rs 9.74 in Q2FY27, declining by 8.72% QoQ from Rs 10.67 in Q1FY27, dropping by 35.02% YoY from Rs 14.99 in Q2FY26, and stood at Rs 20.42 for H1FY27, down by 34.38% YoY against Rs 31.12 in H1FY26. Achin Gupta, MD & Global CEO, Cipla, said: “We are pleased to share that we continue to make considerable progress across our focused markets. In Q2FY27, we delivered global revenues of Rs 7,404 crore with a sequential growth of 4% QoQ, while EBITDA margin expanded by 200 basis points QoQ to 18.7%. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered robust growth, with key therapies outpacing the market. The U.S. business posted revenue of USD 172 million during the quarter, continuing its sequential growth trajectory. We expect North America performance to remain supported by our upcoming product pipeline. South Africa private market business continued to outperform the market, growing approximately 1.3x faster than the market. We continue to focus on sustained growth in our core businesses, improving productivity, strengthening our pipeline in order to serve patients with trusted, high-quality medicines.” Result PDF